Please ensure Javascript is enabled for purposes of website accessibility

2 SPAC Stocks That Could Be 10-Baggers

By Keith Speights - Mar 14, 2021 at 6:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They could even deliver greater gains than just a 10-times return.

I apologize if you're burned out from reading about special purpose acquisition companies (SPACs). It does seem like everywhere you look these days, SPACs are crawling out of the woodwork. And many of them aren't very attractive.

The reality, though, is that there are still some good SPACs mixed in with the duds. And there are even a few that could be massive winners over the next few years. Here are two SPAC stocks that I think could realistically be 10-baggers.

Fingers stacking wood blocks that spell Special Purpose Acquisition Company.

Image source: Getty Images.

A different kind of space company

William Shatner talked about space being the final frontier on the old Star Trek TV series. He was referring to outer space. But there's a highly lucrative frontier with inner space, too. I'm talking about the physical space inside of buildings and homes.

Gore Holdings VI (GHVI) is a SPAC that's getting ready to profit from the inner-space opportunity. It plans to merge with spatial-data pioneer Matterport in the second quarter. What exactly is spatial data? It's the transformation of physical spaces and their contents into 3D virtual models.

Matterport single-handedly defined the spatial-data category in 2011. It has digitized over 10 billion square feet of space in millions of buildings in more than 150 countries. In doing so, Matterport has built the biggest spatial data library in the world.

How can Gore Holdings VI/Matterport become a 10-bagger? It's pretty simple. The company makes its money primarily through a software-as-a-service model that creates constantly increasing recurring revenue as new customers sign up. And a lot of new customers are signing up: Matterport's subscriber base expanded more than 500% last year.

Matterport has attracted more than 250,000 customers so far, including over 13% of the Fortune 1000. However, there's still a big untapped market to go after -- 4 billion buildings and 20 billion spaces. The company estimates this represents a total addressable market of $240 billion.

No, Matterport won't capture this entire market. But Gore Holdings VI can easily deliver a 10 times return with Matterport grabbing only a sliver of the pie.

The SPAC stock's market cap currently stands at under $750 million. Assuming a price-to-sales ratio of 5, Matterport would need to claim a market share of only around 0.6% to be a 10-bagger. The company thinks it will be roughly halfway there by 2025. And a 10-times return could be too conservative: "Couch Investor" podcaster Neil Rozenbaum thinks Matterport could deliver a 15 times gain over the long run.

Tissue, please

Rajiv Shukla has already taken one promising company public via a SPAC merger with DermTech. Now, his Alpha Healthcare Acquisition Corp (AHAC) SPAC hopes to bring another healthcare winner to market with its planned merger with Humacyte.

Humacyte hopes to revolutionize medicine with its off-the-shelf bioengineered human tissue. The company focuses especially on human acellular vessels (HAVs). These HAVs are bioengineered blood vessels that are highly resistant to infection.

So far, Humacyte has successfully completed five phase 2 clinical studies evaluating the use of HAVs in hemodialysis access and peripheral arterial disease. It now has three phase 3 studies in process for vascular trauma and arteriovenous access. These studies are expected to wrap up in 2023. And that's when Humacyte hopes to launch its first product targeting vascular trauma.

Over the next six years, the company thinks that it will be able to win regulatory approvals for bioengineered tissues for use in several other indications. The most ambitious of these is a biovascular pancreas for individuals with type 1 diabetes.

Humacyte estimates that its HAV products could generate peak annual sales of more than $12 billion. This assumes, of course, that those products win regulatory approvals. To be sure, there's a risk that won't happen.

However, the company's chances appear to be pretty good at this point. Over 430 patients have been treated with its HAVs thus far in clinical studies. That's more than 800 patient years of clinical data. And no patient has experienced an immunological rejection.

Alpha Healthcare Acquisition Corp's market cap is below $200 million right now. It's easy to envision the healthcare stock becoming a 10-bagger within a few years if Humacyte's technology proves to be successful in clinical studies. This SPAC stock appears to be a high-risk, potentially high-reward alternative that aggressive investors will probably want to consider.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alpha Healthcare Acquisition Corp. Stock Quote
Alpha Healthcare Acquisition Corp.
AHAC
Gores Holdings VI, Inc. Stock Quote
Gores Holdings VI, Inc.
GHVI
DermTech, Inc. Stock Quote
DermTech, Inc.
DMTK
$6.02 (-3.37%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.